BCDA BioCardia (BCDA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000925741
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter
What the filings say about BCDA
Insiders, 180 days
+$153.5K net bought
2 buyers
BioCardia insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BioCardia, Inc. insiders bought a net $153.5K of stock across 104 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 84 earlier Form 4 trades (code P or S) here by this insider (84 buys), the last on Oct 15, 2026.
- +2.7% median (+3.4% mean) 90-day return after 24 previous buys.
- The trade is 0.1% of the 385,385 shares held after it.
- No other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Altman Peter bought about $285 of BCDA on Oct 16, 2026; 12 funds added in the latest 13F quarter.Context
- 83 earlier Form 4 trades (code P or S) here by this insider (83 buys), the last on Sep 29, 2026.
- +4.4% median (+3.7% mean) 90-day return after 25 previous buys.
- The trade is 0.1% of the 385,085 shares held after it.
- No other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Altman Peter bought about $190 of BCDA on Oct 15, 2026; 12 funds added in the latest 13F quarter.Context
- 82 earlier Form 4 trades (code P or S) here by this insider (82 buys), the last on Sep 23, 2026.
- +2.7% median (+2.3% mean) 90-day return after 26 previous buys.
- The trade is 0.3% of the 384,885 shares held after it.
- No other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Altman Peter bought about $1.0K of BCDA on Sep 29, 2026; 12 funds added in the latest 13F quarter.Context
- 81 earlier Form 4 trades (code P or S) here by this insider (81 buys), the last on Sep 3, 2026.
- +0.9% median (+1.2% mean) 90-day return after 27 previous buys.
- The trade is 0.5% of the 383,885 shares held after it.
- No other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Altman Peter bought about $2.0K of BCDA on Sep 23, 2026; 12 funds added in the latest 13F quarter.Context
- 80 earlier Form 4 trades (code P or S) here by this insider (80 buys), the last on Aug 17, 2026.
- +0.9% median (+0.2% mean) 90-day return after 28 previous buys.
- The trade is 0.2% of the 381,985 shares held after it.
- No other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Altman Peter bought about $872 of BCDA on Sep 3, 2026; 12 funds added in the latest 13F quarter.104 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$153.5K over 180 days
+$15.0K over 90 days
more than 79% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 79% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.0% of the float short (float per yahoo 2026-10-26) · 1.3 days to cover · settled 2026-09-30
below 54% of Pharma & Biotech
What changed in the last 30 days
Oct 20President and CEO Altman Peter bought $1.5K (3 trades, Sep 29 to Oct 16)
Watch BCDA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-34.2%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BCDA: institutional holders (13F)
13F holdings, latest reported quarter
397,594 sh
$493.0K
300,000 sh
$372.0K
124,591 sh
$154.5K
120,382 sh
$149.3K
77,619 sh
$96.2K
Congress trades in BCDA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BCDA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BCDA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$55.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$85.6K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$9.8K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$897 position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$68.9K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$3.0K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 3
0 active
2
Not applicable
2 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Peter Altman
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$493.4K
$423.5K
$303.4K
-78%
n/a
2023
$862.8K
$600.1K
$450.6K
-68%
n/a
2022
$901.9K
$907.2K
$477.4K
+8%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $153.5K bought by insiders over 180 days, 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.
BCDA financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM BCDA
| FY Dec 2025 | $0 |
| FY Dec 2024 | $58.0K |
| FY Dec 2023 | $477.0K |
| FY Dec 2022 | $1.4M |
| FY Dec 2021 | $1.0M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM BCDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -880.7% |
| FY Dec 2021 | -1,244% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BCDA
| FY Dec 2025 | -$7.4M |
| FY Dec 2024 | -$7.9M |
| FY Dec 2023 | -$10.0M |
| FY Dec 2022 | -$10.6M |
| FY Dec 2021 | -$10.5M |
| Jun 2026 | -$1.7M |
| Mar 2026 | -$1.7M |
| Dec 2025 | -$2.5M |
| Sep 2025 | -$1.7M |
| Jun 2025 | -$1.6M |
| Mar 2025 | -$1.6M |
| Dec 2024 | -$2.4M |
| Sep 2024 | -$2.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity BCDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt BCDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-1,803%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BCDA
| FY Dec 2025 | -950.1% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -703.6% |
| FY Dec 2022 | -156.0% |
| FY Dec 2021 | -85.4% |
| Jun 2026 | -1,803% |
| Mar 2026 | n/a |
| Dec 2025 | -950.1% |
| Sep 2025 | -317.5% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -737.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-214.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BCDA
| FY Dec 2025 | -230.6% |
| FY Dec 2024 | -236.8% |
| FY Dec 2023 | -181.1% |
| FY Dec 2022 | -93.3% |
| FY Dec 2021 | -64.5% |
| Jun 2026 | -214.5% |
| Mar 2026 | -401.0% |
| Dec 2025 | -230.6% |
| Sep 2025 | -137.6% |
| Jun 2025 | -353.2% |
| Mar 2025 | -346.4% |
| Dec 2024 | -236.8% |
| Sep 2024 | -154.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital BCDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1,289%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BCDA
| FY Dec 2025 | -694.5% |
| FY Dec 2024 | -2,046% |
| FY Dec 2023 | -416.8% |
| FY Dec 2022 | -130.7% |
| FY Dec 2021 | -81.0% |
| Jun 2026 | -1,289% |
| Mar 2026 | n/a |
| Dec 2025 | -694.5% |
| Sep 2025 | -274.1% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -2,046% |
| Sep 2024 | -404.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing BCDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value BCDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-54.3%
TTM free cash flow over market value at close 2026-10-27
FCF yield BCDA
| FY Dec 2025 | -56.1% |
| FY Dec 2024 | -79.0% |
| FY Dec 2023 | -4.7% |
| FY Dec 2022 | -1.9% |
| FY Dec 2021 | -2.1% |
| Jun 2026 | -53.7% |
| Mar 2026 | -56.6% |
| Dec 2025 | -56.1% |
| Sep 2025 | -98.5% |
| Jun 2025 | -82.4% |
| Mar 2025 | -67.1% |
| Dec 2024 | -79.0% |
| Sep 2024 | -110.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing BCDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $58.0K | $477.0K | $1.4M |
| Operating income | -$8.3M | -$8.0M | -$11.6M | -$11.9M |
| Net income | -$8.2M | -$7.9M | -$11.6M | -$11.9M |
| Operating cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M |
| Cash | $2.5M | $2.4M | $1.1M | $7.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
BCDA Stock Sonar score 5/7 axes
Find similar shapesCompareBCDA ranks highest on insider conviction (79th percentile) and risk and compliance (79th), and lowest on growth (1st), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BCDA filings, in plain words
Are BioCardia insiders buying or selling BCDA?
In the 180 days to 2026-10-28, BioCardia insiders were net buyers, a net $153.5K across purchases and sales reported on Form 4, by 2 buyers.
Read the full summary
In the 180 days to 2026-10-28, BioCardia insiders were net buyers of BCDA, a net $153.5K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
